Asalya's application for a new drug in China has been given priority review by AstraZeneca for the treatment of non-small cell lung cancer.

On July 29, 2020, AstraZeneca announced that the State Drug Administration of China (NSCLC) has officially included in the priority review the listing of new drug applications for Savolitinib (Volitinib) for the treatment of interstitial epithelial conversion factor (MET) No. 14 exosome jump.
Savolitinib is a MET receptor tyrosine kinase inhibitor developed by Huang Pharma and AstraZeneca to treat non-small cell lung cancer (NSCLC), the first selective MET inhibitor in China, to treat interstitial epithelial transtrother conversion factor (MET) No. 14 exosome jump mutation.
break through the treatment status quo, for MET rare mutation patients to bring new hope china each year more than 774,000 new cases of lung cancer, accounting for 37% of the world's new cases of lung cancer. about 80-85% of lung cancer sourcing
is non-small cell lung cancer.
estimates that about 2-3% of non-small cell lung cancer patients will experience MET14 exon jumps.
for many years, met rare mutant lung cancer patients have been in trouble, patient prognosis is poor, insensitive to existing standard treatment, in clinical always lack of effective targeted drugs.
Savolitinib is an oral, highly selective small molecule MET inhibitor whose new drug listing application is based on an ongoing Savolitinib single drug treatment for met14 extrinsic NSCLC patients with previous systemic treatment failure or non-acceptance of chemotherapy in China Phase II Clinicaltrials.gov Registration Number: NCT02897479).
china's local innovation, the first to benefit domestic patients it is worth mentioning that Savolitinib is the country's 1.1 innovative drugs, as China's local pharmaceutical companies hatched innovative original research target drugs, achieved a breakthrough from zero to one.
this means that for the rare mutation of MET, China has independently achieved drug first, local research and development and international integration.
2011, He and Huang Pharmaceuticals and AstraZeneca signed a global patent licensing, co-development and commercialization agreement with Savolitinib.
Savolitinib's global development program includes non-small cell lung cancer, kidney cancer, and other MET-driven tumors.
Savolitinib's independent research and development, local listing, and the future road to the international world, highlighting the future of china's innovation to the world, to promote the pace of globalization of domestic innovative drugs.
Priority Review Priority Review is a potential new drug, clinically urgently needed drug or ?? Vaccines, drugs for the prevention and treatment of diseases such as major infectious diseases and rare diseases, and new varieties or dosage forms for children.
potential new drugs may have clear clinical value for the prevention and treatment of diseases that seriously endanger life or seriously affect quality of life.
applications for listing of new drugs included in the priority review qualification may be given priority allocation of resources by the State Drug Administration during the review and approval process.
about Hutchison Pharma and Huang China Pharmaceutical Technology Co., Ltd. ("Chi-Med") (NASDAQ /LSE: HCM) is an innovative biopharmaceutical company that has been working for the past 20 years to identify and develop targeted drugs and immunotherapy for the treatment of cancer and autoimmune diseases.
currently, there are nine cancer-fighting drug candidates in the global development of Hutchison Pharmaceuticals, and has an extensive commercial network in China's domestic market.
AstraZeneca AstraZeneca is a scientifically supreme global biopharmaceutical company focused on the development, production and marketing of prescription drugs, focusing on the three main disease areas of oncology, cardiovascular, kidney and metabolism, and respiration.
AstraZeneca operates in more than 100 countries, and innovative drugs reach millions of patients worldwide.
References: 1. Global Cancer Observatory. China Fact Sheet. gco.iarc.fr/today/data/factsheets/populations/160-china-fact-sheets.pdf.2. American Cancer Society.
M et al. "MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are YOr Associated With Er Age and Stage-Dependent MET Met Biao and c-Met Overexpression." Journal of Clinical Oncology 2016;34 (7): 721-730. Doi: 10.1200/JCO.2015.63.4600.S Lu, J Fang, X Li, L Cao, J Zhou, Q Guo, Z Liang, Y Cheng, L Jiang, N Yang, Z Han, J Shi, Y Chen, H Xu, H Zhang, D Zhang, J. "Phase II study of savolitinib in patients (pts) with the curly sarcomatoid carcinoma (PSC) and other type of non-small cell lung cancer (NSCLC) met exon 14ingings (METexs) 2020 ASCO (9519.5. National Drug Administration, "Priority Review and Approval Procedurefor Drug Market Licensing (Trial)" Source: MedSci !-- Content Presentation End- !-- Determine whether the login ends.